Updates in Management of SARS-CoV-2 Infection
Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) has spread worldwide from the beginning of 2020. The infection is mostly asymptomatic but some patients may develop COVID‑19 (coronavirus disease 2019) with a severe or critical course leading to pneumonia, acute respiratory distress syndr...
Na minha lista:
| Formato: | Online |
|---|---|
| Idioma: | inglês |
| Publicado em: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Assuntos: | |
| Acesso em linha: | ONIX_20221025_9783036553894_78 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|
| _version_ | 1869516440865865728 |
|---|---|
| collection | Directory of Open Access Books |
| description | Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) has spread worldwide from the beginning of 2020. The infection is mostly asymptomatic but some patients may develop COVID‑19 (coronavirus disease 2019) with a severe or critical course leading to pneumonia, acute respiratory distress syndrome, and multiorgan failure. Apart from the virus‑related damage of the lungs, pathomechanism of the disease seems to be linked to thromboembolism and inflammation accompanied by overproduction of proinflammatory cytokines, termed a cytokine storm, responsible for multiorgan damage and death. Since the development of a new therapeutic molecule, dedicated strictly to a particular virus is time‑consuming, physicians and scientists have started to test and repurpose old medications. Unfortunately, after one year of pandemics, there is still a lack of optimal therapy and no clear indicators of recovery. A major issue is also insufficient knowledge on predictors of the severe or deadly course of the disease, which could also help to switch from one therapeutic option to another. Due to many gaps still existing in the management of COVID-19, there is a need for the accumulation of new data particularly from real-world experience, which could be applicable to practice guidelines. The objective of this special issue of the Journal of Clinical Medicine is to provide an update on the mangement for the diagnostic workup and pharmacotherapy of SARS‑CoV‑2 infection. |
| format | Online |
| id | doab-20.500.12854ir-93224 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-932242024-03-30T23:21:54Z Updates in Management of SARS-CoV-2 Infection Flisiak, Robert COVID-19 SARS-CoV-2 interleukin-6 tocilizumab therapy coronavirus disease 2019 cytokines severity prognosis mortality kidney failure rapid diagnostic test antigen detection Cytomegalovirus co-infections critical care liver markers inflammation morbidity personalized medicine liver functional tests COVID-19 pneumonia meta-analysis trial sequential analysis children clinical presentation coronavirus disease 2019 (COVID-19) epidemiology severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) clinical outcome symptomatology pandemic angiotensin 1 receptor (AT1R) AT1R concentration angiotensin II symptoms’ severity diagnosis artificial intelligence medical imaging systematic umbrella review methodological credibility PCR test COVID-19 diagnosis Charlson Comorbidities Index cluster analysis longitudinal cluster individualized management n/a thema EDItEUR::M Medicine and Nursing Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) has spread worldwide from the beginning of 2020. The infection is mostly asymptomatic but some patients may develop COVID‑19 (coronavirus disease 2019) with a severe or critical course leading to pneumonia, acute respiratory distress syndrome, and multiorgan failure. Apart from the virus‑related damage of the lungs, pathomechanism of the disease seems to be linked to thromboembolism and inflammation accompanied by overproduction of proinflammatory cytokines, termed a cytokine storm, responsible for multiorgan damage and death. Since the development of a new therapeutic molecule, dedicated strictly to a particular virus is time‑consuming, physicians and scientists have started to test and repurpose old medications. Unfortunately, after one year of pandemics, there is still a lack of optimal therapy and no clear indicators of recovery. A major issue is also insufficient knowledge on predictors of the severe or deadly course of the disease, which could also help to switch from one therapeutic option to another. Due to many gaps still existing in the management of COVID-19, there is a need for the accumulation of new data particularly from real-world experience, which could be applicable to practice guidelines. The objective of this special issue of the Journal of Clinical Medicine is to provide an update on the mangement for the diagnostic workup and pharmacotherapy of SARS‑CoV‑2 infection. 2022-10-25T09:02:51Z 2022-10-25T09:02:51Z 2022 book ONIX_20221025_9783036553894_78 9783036553894 9783036553900 https://directory.doabooks.org/handle/20.500.12854/93224 eng application/octet-stream Attribution 4.0 International https://mdpi.com/books/pdfview/book/6122 https://mdpi.com/books/pdfview/book/6122 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-5390-0 10.3390/books978-3-0365-5390-0 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036553894 9783036553900 198 open access |
| spellingShingle | COVID-19 SARS-CoV-2 interleukin-6 tocilizumab therapy coronavirus disease 2019 cytokines severity prognosis mortality kidney failure rapid diagnostic test antigen detection Cytomegalovirus co-infections critical care liver markers inflammation morbidity personalized medicine liver functional tests COVID-19 pneumonia meta-analysis trial sequential analysis children clinical presentation coronavirus disease 2019 (COVID-19) epidemiology severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) clinical outcome symptomatology pandemic angiotensin 1 receptor (AT1R) AT1R concentration angiotensin II symptoms’ severity diagnosis artificial intelligence medical imaging systematic umbrella review methodological credibility PCR test COVID-19 diagnosis Charlson Comorbidities Index cluster analysis longitudinal cluster individualized management n/a thema EDItEUR::M Medicine and Nursing Updates in Management of SARS-CoV-2 Infection |
| title | Updates in Management of SARS-CoV-2 Infection |
| title_full | Updates in Management of SARS-CoV-2 Infection |
| title_fullStr | Updates in Management of SARS-CoV-2 Infection |
| title_full_unstemmed | Updates in Management of SARS-CoV-2 Infection |
| title_short | Updates in Management of SARS-CoV-2 Infection |
| title_sort | updates in management of sars cov 2 infection |
| topic | COVID-19 SARS-CoV-2 interleukin-6 tocilizumab therapy coronavirus disease 2019 cytokines severity prognosis mortality kidney failure rapid diagnostic test antigen detection Cytomegalovirus co-infections critical care liver markers inflammation morbidity personalized medicine liver functional tests COVID-19 pneumonia meta-analysis trial sequential analysis children clinical presentation coronavirus disease 2019 (COVID-19) epidemiology severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) clinical outcome symptomatology pandemic angiotensin 1 receptor (AT1R) AT1R concentration angiotensin II symptoms’ severity diagnosis artificial intelligence medical imaging systematic umbrella review methodological credibility PCR test COVID-19 diagnosis Charlson Comorbidities Index cluster analysis longitudinal cluster individualized management n/a thema EDItEUR::M Medicine and Nursing |
| topic_facet | COVID-19 SARS-CoV-2 interleukin-6 tocilizumab therapy coronavirus disease 2019 cytokines severity prognosis mortality kidney failure rapid diagnostic test antigen detection Cytomegalovirus co-infections critical care liver markers inflammation morbidity personalized medicine liver functional tests COVID-19 pneumonia meta-analysis trial sequential analysis children clinical presentation coronavirus disease 2019 (COVID-19) epidemiology severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) clinical outcome symptomatology pandemic angiotensin 1 receptor (AT1R) AT1R concentration angiotensin II symptoms’ severity diagnosis artificial intelligence medical imaging systematic umbrella review methodological credibility PCR test COVID-19 diagnosis Charlson Comorbidities Index cluster analysis longitudinal cluster individualized management n/a thema EDItEUR::M Medicine and Nursing |
| url | ONIX_20221025_9783036553894_78 |